CHICAGO — The results of the integrated SAKURA program showed every-other-month dosing with intravitreal sirolimus improved ocular inflammation and vitreous haze in patients with non-infectious uveitis, according to a speaker here.
Researchers evaluated the safety and efficacy of intravitreal injections of 44 µg and 440 µg sirolimus (Santen) for the treatment of active non-infectious uveitis of the posterior segment. Study of an 880 µg sirolimus dose was abandoned after researchers determined the 440 µg dose to have the better benefit-to-risk profile, Alay S.
Uncategorized